Shelton Wealth Management LLC Lowers Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shelton Wealth Management LLC lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,773 shares of the medical equipment provider’s stock after selling 1,196 shares during the quarter. Shelton Wealth Management LLC’s holdings in Lantheus were worth $1,051,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC increased its position in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after buying an additional 435,445 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider’s stock valued at $120,510,000 after buying an additional 30,891 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC increased its position in Lantheus by 39.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider’s stock valued at $87,124,000 after buying an additional 273,838 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Finally, Truist Financial reduced their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $132.67.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.4%

Lantheus stock opened at $78.99 on Friday. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of 22.44 and a beta of 0.11. The stock has a fifty day simple moving average of $87.25 and a two-hundred day simple moving average of $91.07. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.69 EPS. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.